Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2.
Asymptomatic Infections
COVID-19
/ immunology
Cell Proliferation
Cohort Studies
DNA-Directed RNA Polymerases
/ immunology
Evolution, Molecular
Female
Health Personnel
Humans
Male
Membrane Proteins
/ immunology
Memory T Cells
/ cytology
Multienzyme Complexes
/ immunology
SARS-CoV-2
/ enzymology
Seroconversion
Transcription, Genetic
/ immunology
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
17
06
2021
accepted:
27
10
2021
pubmed:
11
11
2021
medline:
12
1
2022
entrez:
10
11
2021
Statut:
ppublish
Résumé
Individuals with potential exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) do not necessarily develop PCR or antibody positivity, suggesting that some individuals may clear subclinical infection before seroconversion. T cells can contribute to the rapid clearance of SARS-CoV-2 and other coronavirus infections
Identifiants
pubmed: 34758478
doi: 10.1038/s41586-021-04186-8
pii: 10.1038/s41586-021-04186-8
pmc: PMC8732273
doi:
Substances chimiques
IFI27 protein, human
0
Membrane Proteins
0
Multienzyme Complexes
0
DNA-Directed RNA Polymerases
EC 2.7.7.6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
110-117Subventions
Organisme : Medical Research Council
ID : MR/V027883/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_20031
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S019553/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R02622X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/W020610/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 26603
Pays : United Kingdom
Organisme : MRF
ID : MRF_MRF-044-0001-RG-SWADL
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_20060
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/CRTF/21/24128
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 214191/Z/18/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V036939/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R008698/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/18/21/33447
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 207511/Z/17/Z
Pays : United Kingdom
Investigateurs
Hakam Abbass
(H)
Aderonke Abiodun
(A)
Mashael Alfarih
(M)
Zoe Alldis
(Z)
Mervyn Andiapen
(M)
Jessica Artico
(J)
João B Augusto
(JB)
Georgina L Baca
(GL)
Sasha N L Bailey
(SNL)
Anish N Bhuva
(AN)
Alex Boulter
(A)
Ruth Bowles
(R)
Rosemary J Boyton
(RJ)
Olivia V Bracken
(OV)
Ben O'Brien
(B)
Tim Brooks
(T)
Natalie Bullock
(N)
David K Butler
(DK)
Gabriella Captur
(G)
Nicola Champion
(N)
Carmen Chan
(C)
David Collier
(D)
Jorge Couto de Sousa
(JC)
Xose Couto-Parada
(X)
Teresa Cutino-Mogue
(T)
Rhodri H Davies
(RH)
Brooke Douglas
(B)
Cecilia Di Genova
(C)
Keenan Dieobi-Anene
(K)
Anaya Ellis
(A)
Karen Feehan
(K)
Malcolm Finlay
(M)
Marianna Fontana
(M)
Nasim Forooghi
(N)
Celia Gaier
(C)
Derek Gilroy
(D)
Matt Hamblin
(M)
Gabrielle Harker
(G)
Jacqueline Hewson
(J)
Lauren M Hickling
(LM)
Aroon D Hingorani
(AD)
Lee Howes
(L)
Alun Hughes
(A)
Gemma Hughes
(G)
Rebecca Hughes
(R)
Ivie Itua
(I)
Victor Jardim
(V)
Wing-Yiu Jason Lee
(WJ)
Melanie Petra Jensen
(MP)
Jessica Jones
(J)
Meleri Jones
(M)
George Joy
(G)
Vikas Kapil
(V)
Hibba Kurdi
(H)
Jonathan Lambourne
(J)
Kai-Min Lin
(KM)
Sarah Louth
(S)
Vineela Mandadapu
(V)
Áine McKnight
(Á)
Katia Menacho
(K)
Celina Mfuko
(C)
Oliver Mitchelmore
(O)
Christopher Moon
(C)
Diana Munoz-Sandoval
(D)
Sam M Murray
(SM)
Mahdad Noursadeghi
(M)
Ashley Otter
(A)
Susana Palma
(S)
Ruth Parker
(R)
Kush Patel
(K)
Babita Pawarova
(B)
Steffen E Petersen
(SE)
Brian Piniera
(B)
Franziska P Pieper
(FP)
Daniel Pope
(D)
Mary Prossora
(M)
Lisa Rannigan
(L)
Alicja Rapala
(A)
Catherine J Reynolds
(CJ)
Amy Richards
(A)
Matthew Robathan
(M)
Genine Sambile
(G)
Amanda Semper
(A)
Andreas Seraphim
(A)
Mihaela Simion
(M)
Angelique Smit
(A)
Michelle Sugimoto
(M)
Stephen Taylor
(S)
Nigel Temperton
(N)
Stephen Thomas
(S)
George D Thornton
(GD)
Art Tucker
(A)
Jessry Veerapen
(J)
Mohit Vijayakumar
(M)
Sophie Welch
(S)
Theresa Wodehouse
(T)
Lucinda Wynne
(L)
Dan Zahedi
(D)
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2021. The Author(s).
Références
Tan, A. T. et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 34, 108728 (2021).
pubmed: 33516277
pmcid: 7826084
doi: 10.1016/j.celrep.2021.108728
Oberhardt, V. et al. Rapid and stable mobilization of CD8
pubmed: 34320609
pmcid: 8426185
doi: 10.1038/s41586-021-03841-4
Zhao, J. J. et al. Airway memory CD4
pubmed: 27287409
pmcid: 4917442
doi: 10.1016/j.immuni.2016.05.006
Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183, 158–168 (2020).
pubmed: 32979941
pmcid: 7427556
doi: 10.1016/j.cell.2020.08.017
Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 370, 89–94 (2020).
pubmed: 32753554
pmcid: 7574914
doi: 10.1126/science.abd3871
Nelde, A. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat. Immunol. 22, 74–85 (2021).
pubmed: 32999467
doi: 10.1038/s41590-020-00808-x
Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 587, 270–274 (2020).
pubmed: 32726801
doi: 10.1038/s41586-020-2598-9
Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 457–462 (2020).
pubmed: 32668444
doi: 10.1038/s41586-020-2550-z
Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489–1501 (2020).
pubmed: 32473127
pmcid: 7237901
doi: 10.1016/j.cell.2020.05.015
Schulien, I. et al. Characterization of pre-existing and induced SARS-CoV-2-specific CD8
pubmed: 33184509
doi: 10.1038/s41591-020-01143-2
Loyal, L. et al. Cross-reactive CD4
pubmed: 34465633
doi: 10.1126/science.abh1823
Perlman, S. & Netland, J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat. Rev. Microbiol. 7, 439–450 (2009).
pubmed: 19430490
pmcid: 2830095
doi: 10.1038/nrmicro2147
Yamada, T. et al. RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells. Nat. Immunol. 22, 820–828 (2021).
pubmed: 33976430
doi: 10.1038/s41590-021-00942-0
Gupta, R. K. et al. Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study. Lancet Microbe 2, E508–E517 (2021).
Mallajosyula, V. et al. CD8
pubmed: 34210785
doi: 10.1126/sciimmunol.abg5669
Reynolds, C. J. et al. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci. Immunol. 5, eabf3698 (2020).
pubmed: 33361161
pmcid: 8101131
doi: 10.1126/sciimmunol.abf3698
Low, J. S. et al. Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2. Science 372, eabg8985 (2021).
doi: 10.1126/science.abg8985
Ferretti, A. P. et al. Unbiased screens show CD8
pubmed: 33128877
pmcid: 7574860
doi: 10.1016/j.immuni.2020.10.006
da Silva Antunes, R. et al. Differential T-cell reactivity to endemic coronaviruses and SARS-CoV-2 in community and health care workers. J. Infect. Dis. 224, 70–80 (2021).
pubmed: 33822097
pmcid: 8083569
doi: 10.1093/infdis/jiab176
Wang, Z. et al. Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection. Nat. Commun. 12, 1724 (2021).
pubmed: 33741972
pmcid: 7979809
doi: 10.1038/s41467-021-22036-z
Ogbe, A. et al. T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nat. Commun. 12, 2055 (2021).
pubmed: 33824342
pmcid: 8024333
doi: 10.1038/s41467-021-21856-3
Gallais, F. et al. Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without Seroconversion, France. Emerg. Infect. Dis. 27, 113–121 (2021).
pmcid: 7774579
doi: 10.3201/eid2701.203611
Wiegand, J. et al. HBV-specific T-cell responses in healthy seronegative sexual partners of patients with chronic HBV infection. J. Viral Hepat. 17, 631–639 (2010).
pubmed: 19889141
Promadej, N. et al. Broad human immunodeficiency virus (HIV)-specific T cell responses to conserved HIV proteins in HIV-seronegative women highly exposed to a single HIV-infected partner. J. Infect. Dis. 187, 1053–1063 (2003).
pubmed: 12660919
doi: 10.1086/368127
Heller, T. et al. Occupational exposure to hepatitis C virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study. J. Infect. Dis. 208, 1020–1025 (2013).
pubmed: 23801608
pmcid: 3749009
doi: 10.1093/infdis/jit270
Rowland-Jones, S. et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1, 59–64 (1995).
pubmed: 7584954
doi: 10.1038/nm0195-59
Turtle, L. et al. Human T cell responses to Japanese encephalitis virus in health and disease. J. Exp. Med. 213, 1331–1352 (2016).
pubmed: 27242166
pmcid: 4925015
doi: 10.1084/jem.20151517
Manisty, C. et al. Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS-CoV-2 infection. EBioMedicine 65, 103259 (2021).
pubmed: 33662833
pmcid: 7920816
doi: 10.1016/j.ebiom.2021.103259
Jeffery-Smith, A. et al. SARS-CoV-2-specific memory B cells can persist in the elderly who have lost detectable neutralising antibodies. J. Clin. Invest., https://doi.org/10.1172/JCI152042 (2021).
Chandran, A. et al. Non-severe SARS-CoV-2 infection is characterised by very early T cell proliferation independent of type 1 interferon responses and distinct from other acute respiratory viruses. Preprint at https://doi.org/10.1101/2021.03.30.21254540 (2021).
Kalimuddin, S. et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Med 2, 682–688 (2021).
pubmed: 33851143
doi: 10.1016/j.medj.2021.04.003
Tan, C. C. S. et al. Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses. Infect. Genet. Evol. 95, 105075 (2021).
pubmed: 34509646
pmcid: 8428999
doi: 10.1016/j.meegid.2021.105075
Buckley, P. R., Lee, C. H., Pinho, M. P. & Babu, R. O. HLA-dependent variation in SARS-CoV-2 CD8
Nelde, A. et al. SARS-CoV-2 T-cell epitopes define heterologous and COVID-19-induced T-cell recognition. Nat. Immunol. 22, 74–85 (2020).
pubmed: 32999467
doi: 10.1038/s41590-020-00808-x
Grifoni, A. et al. SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19. Cell Host Microbe 29, 1076–1092 (2021).
pubmed: 34237248
pmcid: 8139264
doi: 10.1016/j.chom.2021.05.010
Anderson, E. M. et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell 184, 1858–1864 (2021).
pubmed: 33631096
pmcid: 7871851
doi: 10.1016/j.cell.2021.02.010
Clerici, M. et al. T-cell proliferation to subinfectious SIV correlates with lack of infection after challenge of macaques. AIDS 8, 1391–1395 (1994).
doi: 10.1097/00002030-199410000-00004
Werner, J. M., Abdalla, A., Gara, N., Ghany, M. G. & Rehermann, B. The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity. Gastroenterology 145, 1026–1034 (2013).
pubmed: 23916846
doi: 10.1053/j.gastro.2013.07.044
Sagar, M. et al. Recent endemic coronavirus infection is associated with less-severe COVID-19. J. Clin. Invest. 131, e143380 (2021).
pmcid: 7773342
doi: 10.1172/JCI143380
Ng, K. W. et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 370, 1339–1343 (2020).
pubmed: 33159009
pmcid: 7857411
doi: 10.1126/science.abe1107
Yang, F. et al. Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues. Science 372, 738–741 (2021).
pubmed: 33846272
pmcid: 8139427
doi: 10.1126/science.abf6648
Wyllie, D. et al. SARS-CoV-2 responsive T cell numbers and anti-Spike IgG levels are both associated with protection from COVID-19: a prospective cohort study in keyworkers. Preprint at https://doi.org/10.1101/2020.11.02.20222778 (2021).
Cervia, C. et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J. Allergy Clin. Immunol. 147, 545–557 (2021).
pubmed: 33221383
doi: 10.1016/j.jaci.2020.10.040
Dangi, T. et al. SARS coronavirus vaccines protect against different coronaviruses. Preprint at https://doi.org/10.1101/2021.06.01.446491 (2021).
Augusto, J. B. et al. Healthcare Workers Bioresource: study outline and baseline characteristics of a prospective healthcare worker cohort to study immune protection and pathogenesis in COVID-19. Wellcome Open Res. 5, 179 (2020).
pubmed: 33537459
pmcid: 7836029
doi: 10.12688/wellcomeopenres.16051.2
Treibel, T. A. et al. COVID-19: PCR screening of asymptomatic health-care workers at London hospital. Lancet 395, 1608–1610 (2020).
pubmed: 32401714
pmcid: 7206444
doi: 10.1016/S0140-6736(20)31100-4
Reynolds, C. J. et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science 5, eabh1282 (2021).
O’Nions, J. et al. SARS-CoV-2 antibody responses in patients with acute leukaemia. Leukemia 35, 289–292 (2021).
pubmed: 33299142
doi: 10.1038/s41375-020-01103-2
Muir, L. et al. Neutralizing antibody responses after SARS-CoV-2 infection in end-stage kidney disease and protection against reinfection. Kidney Int. Rep. 6, 1799–1809 (2021).
pubmed: 33942026
pmcid: 8081267
doi: 10.1016/j.ekir.2021.03.902
Johnson, M. et al. Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2. J. Clin. Virol. 130, 104572 (2020).
pubmed: 32769024
pmcid: 7396134
doi: 10.1016/j.jcv.2020.104572
Capone, S. et al. Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans. npj Vaccines 5, 94 (2020).
pubmed: 33083029
pmcid: 7550607
doi: 10.1038/s41541-020-00240-0
Roederer, M., Nozzi, J. L. & Nason, M. C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytom. A 79, 167–174 (2011).
doi: 10.1002/cyto.a.21015
Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data—from vision to reality. Eurosurveillance 22, 30494 (2017).
pubmed: 28382917
pmcid: 5388101
doi: 10.2807/1560-7917.ES.2017.22.13.30494
Elbe, S. & Buckland-Merrett, G. Data, disease and diplomacy: GISAID’s innovative contribution to global health. Glob. Chall. 1, 33–46 (2017).
pubmed: 31565258
pmcid: 6607375
doi: 10.1002/gch2.1018
Nei, M. Analysis of gene diversity in subdivided populations. Proc. Natl Acad. Sci. USA 70, 3321–3323 (1973).
pubmed: 4519626
pmcid: 427228
doi: 10.1073/pnas.70.12.3321
Crispell, J., Balaz, D. & Gordon, S. V. HomoplasyFinder: a simple tool to identify homoplasies on a phylogeny. Microb. Genom. 5, e000245 (2019).
pmcid: 6412054
Pollara, G. et al. Exaggerated IL-17A activity in human in vivo recall responses discriminates active tuberculosis from latent infection and cured disease. Sci. Transl. Med. 13, eabg7673 (2021).
pubmed: 33952677
pmcid: 7610803
doi: 10.1126/scitranslmed.abg7673